Role of GSH/GSSG redox couple in osteogenic activity and osteoclastogenic markers of human osteoblast-like SaOS-2 cells

FEBS J. 2013 Feb;280(3):867-79. doi: 10.1111/febs.12075. Epub 2012 Dec 20.

Abstract

This study comprised a comprehensive analysis of the glutathione (GSH) redox system during osteogenic differentiation in human osteoblast-like SaOS-2 cells. For the first time, a clear relationship between expression of specific factors involved in bone remodeling and the changes in the GSH/oxidized GSH (GSSG) redox couple induced during the early phases of the differentiation and mineralization process is shown. The findings show that the time course of differentiation is characterized by a decrease in the GSH/GSSG ratio, and this behavior is also related to the expression of osteoclastogenic markers. Maintenance of a high GSH/GSSG ratio due to GSH exposure in the early phase of this process increases mRNA levels of osteogenic differentiation markers and mineralization. Conversely, these events are decreased by a low GSH/GSSG ratio in a reversible manner. Redox regulation of runt-related transcription factor-2 (RUNX-2) activation through phosphorylation is shown. An inverse relationship between RUNX-2 activation and extracellular signal-regulated kinases related to GSH redox potential is observed. The GSH/GSSG redox couple also affects osteoclastogenesis, mainly through osteoprotegerin down-regulation with an increase in the ratio of receptor activator of NF-κB ligand to osteoprotegerin and vice versa. No redox regulation of receptor activator of NF-κB ligand expression was found. These results indicate that the GSH/GSSG redox couple may have a pivotal role in bone remodeling and bone redox-dysregulated diseases. They suggest therapeutic use of compounds that are able to modulate not just the GSH level but the intracellular redox system through the GSH/GSSG redox couple.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Biomarkers, Tumor / metabolism*
  • Blotting, Western
  • Buthionine Sulfoximine / pharmacology
  • Cell Differentiation / drug effects
  • Cell Line, Tumor
  • Core Binding Factor Alpha 1 Subunit / genetics
  • Core Binding Factor Alpha 1 Subunit / metabolism
  • Enzyme Inhibitors / pharmacology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Glutamate-Cysteine Ligase / antagonists & inhibitors
  • Glutamate-Cysteine Ligase / metabolism
  • Glutathione / metabolism*
  • Glutathione / pharmacology
  • Glutathione Disulfide / metabolism*
  • Humans
  • Osteoblasts / drug effects
  • Osteoblasts / metabolism*
  • Osteoblasts / pathology
  • Osteoclasts / metabolism
  • Osteogenesis / drug effects
  • Osteoprotegerin / genetics
  • Osteoprotegerin / metabolism
  • Oxidation-Reduction
  • RANK Ligand / genetics
  • RANK Ligand / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Biomarkers, Tumor
  • Core Binding Factor Alpha 1 Subunit
  • Enzyme Inhibitors
  • Osteoprotegerin
  • RANK Ligand
  • RUNX2 protein, human
  • Buthionine Sulfoximine
  • Extracellular Signal-Regulated MAP Kinases
  • Glutamate-Cysteine Ligase
  • Glutathione
  • Glutathione Disulfide
  • Acetylcysteine